Trial purpose
Cancer treatment
Tumor type
Lung cancer
Age
18+
Clinical summary
Summary
In this trial, participants will be randomised to the experimental treatment or observation arm. In the experimental arm, participants will receive Nivolumab (1mg/kg IV) and Ipilimumab (3mg/kg IV) as induction therapy once every three weeks for four cycles, followed by 240mg Nivolumab IV as maintenance therapy once every two weeks for a maximum of 12 months.
Conditions
This trial is treating people with limited small cell lung cancer (SCLC)
Eligibility
Inclusion
Inclusion Criteria for enrolment:
Inclusion Criteria for randomisation:
- Chemo-radiotherapy completed per protocol: 4 cycles of chemotherapy, ≥85% of PTV of thoracic radiotherapy, as well as completed, mandatory PCI
- non-PD after chemo-radiotherapy and PCI
- ECOG performance status 0-2
- Recovery of all adverse events to a grade ≤1, except for fatigue, appetite, oesophagitis and renal impairment (where ≤2 is allowed) and alopecia (any grade)
- Women of childbearing potential, including women who had their last menstrual period in the last 2 years, must have a negative serum or urine pregnancy test within 7 days before randomisation.
Exclusion
Exclusion Criteria for enrolment:
- Patient with mixed small-cell and non-small-cell histologic features
- Patient with pleural or pericardial effusions proven to be malignant
- Patients who have had in the past 5 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ ductal carcinoma of the breast (if no RT was involved).
- Patients with other serious diseases or clinical conditions, including but not limited to uncontrolled active infection and any other serious underlying medical processes that could affect the patient's capacity to participate in the study.
- Ongoing clinically serious infections requiring systemic antibiotic or antiviral, antimicrobial, antifungal therapy.
- Known or suspected hypersensitivity to nivolumab or ipilimumab or any of their excipients.
- Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- Documented history of severe autoimmune or immune mediated symptomatic disease that required prolonged (more than 2 months) systemic immunosuppressive (e.g. steroids) treatment, such as but not limited to ulcerative colitis and Crohn´s disease, rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, or autoimmune vasculitis (eg, Wegener's granulomatosis).
- Subjects with an autoimmune paraneoplastic syndrome requiring concurrent immunosuppressive treatment.
- Interstitial lung disease or pulmonary fibrosis
- Women who are pregnant or in the period of lactation.
- Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.
- Patients with any concurrent anticancer systemic therapy (except for chemotherapy cycle 1).
- HIV, active Hepatitis B or Hepatitis C infection
- Previous radiotherapy to the thorax (prior to inclusion), including RT for breast cancer
- Planned radiotherapy to lung of mean dose > 20 Gy or V20 > 35 %
- Patients who received treatment with an investigational drug agent during the 3 weeks before enrolment in the study.
- Prior chemotherapy or radiotherapy for SCLC. Exception: one cycle of chemotherapy (as specified to section 10.2) may be administered prior to enrolment.
Exclusion criteria for randomisation:
- Less than 4 cycles of chemotherapy administered, less than 85% PTV of thoracic radiotherapy delivered, or PCI not completed
- Progressive disease after chemo-radiotherapy and PCI
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
- You are currently being treated on a clinical trial.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Bristol-Myers Squibb (BMS),Ludwig Institute for Cancer Research,European Thoracic Oncology Platform
Scientific Title
A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information